- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00981240
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.
Primary objectives:
- To determine the maximum tolerated dose (MTD) of SAR103168 and to characterize the dose limiting toxicities (DLTs) in the proposed dose regimen
- To evaluate the pharmacokinetic (PK) profile of SAR103168
Secondary objectives:
- To characterize the global safety profile of SAR103168
- To evaluate preliminary anti-leukemia activity
- To investigate the potential induction effect on CYP3A4 and persistence of this effect by using oral midazolam as a probe substrate in patients enrolled into the expanded cohort at the MTD
- To determine the metabolic pathways of SAR103168 and identify the chemical structures of metabolites
- To determine the potential impact of SAR103168 on the QTc interval in patients enrolled at the MTD
Studieöversikt
Detaljerad beskrivning
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30322
- Sanofi-Aventis Investigational Site Number 840003
-
-
New York
-
New York, New York, Förenta staterna, 10021
- Sanofi-Aventis Investigational Site Number 840002
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Sanofi-Aventis Investigational Site Number 840001
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
Patients with refractory/relapsed acute leukemias or high-risk myelodysplastic syndromes with no curative option available including any of the following:
- Patients with de novo or secondary acute myelogenous leukemia (AML) (except acute promyelocytic leukemia), meeting one of the following conditions:
- Refractory or relapsed AML; In case of first relapse the CR duration should be less than 12 months. If the relapse failed at least one prior salvage attempt, the CR duration may be more than 12 months.
- Into the expanded cohort at the MTD, previously untreated AML patients over age 60 with poor- risk cytogenetics who are not eligible for or do not accept induction chemotherapy may also be included.
- Patients with refractory/relapsed acute lymphoblastic leukemia (ALL)
- Patients with high-risk myelodysplastic syndrome (MDS) as defined by the International Prognostic Scoring System
- Patients with chronic myeloid leukemia in blast phase (CML-BP)
Exclusion Criteria:
- performance status > 2
- Active uncontrolled central nervous system leukemia
- Cytotoxic therapy within 2 weeks prior to the first dose of SAR103168. For the non cytotoxic agents/investigational drugs this washout period should be at least 2 weeks or at least 5 half-lives whichever is longer. Hydroxyurea must be stopped at least 24 hours prior to the first dose of SAR103168
- Lack of recovery from toxicities from prior therapies to grade < 1
- White blood cells > 30 x 10^9/L prior to the first dose of SAR103168
- Prior allogeneic stem cell transplantation or donor lymphocytes infusion within 3 months preceding the first dose of SAR103168
Any of the following within 6 months prior to the first dose of SAR103168:
- Myocardial infarction, congestive heart failure, documented angina pectoris, arrhythmia requiring medication (in particular atrial fibrillation or flutter), severe conduction disorder (second or third atrio-ventricular block, pacemaker), coronary/peripheral artery bypass graft surgery
- Arterial or venous thromboembolism, deep venous thrombosis
- Left ventricular ejection fraction < 50% by echocardiography or multiple gated acquisition scan
- Cardiac ischemia on 12-lead ECG
- Baseline QTc-interval > 500 msec
- Hypertension uncontrolled with appropriate therapy
- Active infection (viral, bacterial or fungal) uncontrolled with appropriate therapy
- Major surgery within 6 weeks prior to the first dose of SAR103168
Poor organ function defined by one of the following:
- Total bilirubin > 1.5 x upper limit of normal (ULN) unless related to leukemia (i.e. hemolysis) or Gilbert's syndrome
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT) > 2.5 x ULN
- Serum creatinine > 1.5 x ULN or calculated creatinine clearance < 50 mL/min
- Patients under treatment with potent inhibitors of CYP3A4 unless these treatments may be stopped at least 3 days prior to the first dose of SAR103168
- Patients under treatment with CYP3A4 or CYP2C9 inducers, unless these treatments may be stopped at least 3 days prior to the first dose of SAR103168
- Pregnant or breast-feeding women or refusal to use adequate contraceptive method, when applicable.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Dose escalation
Cohorts of 3 to 6 patients will be included at each dose level.
The starting dose is 1.2mg/m2/day.
The dose will be increased in new cohorts of patients according to toxicities observed during the first 4-week treatment period.
The escalation process will continue until the MTD is determined.
Additional 15 patients will be included at the MTD.
|
Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous infusion |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Incidence of DLTs during the initial 4-week period of treatment
Tidsram: 4 weeks
|
4 weeks
|
Pharmacokinetic parameters of SAR103168
Tidsram: First course: Days 1, 2, 5, 6, and 8; Second and subsequent courses: Day 5 only
|
First course: Days 1, 2, 5, 6, and 8; Second and subsequent courses: Day 5 only
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Global safety profile of SAR103168 based on treatment emergent adverse events (TEAEs), serious adverse events (SAEs), deaths, laboratory abnormalities
Tidsram: Treatment period up to 1 year
|
Treatment period up to 1 year
|
Preliminary evidence of anti-leukemia activity
Tidsram: Treatment period up to 1 year
|
Treatment period up to 1 year
|
Pharmacokinetic parameters of midazolam in the absence and the presence of SAR103168.
Tidsram: During second (Day-1 and Day 5) and forth course (Day 5)
|
During second (Day-1 and Day 5) and forth course (Day 5)
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Farhad Ravandi-Kashani, MD, M.D. Anderson Cancer Center, Houston, Texas
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- TED10416
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Akut myelogen leukemi
-
Massachusetts General HospitalCelgene CorporationAvslutadAkut myelogen leukemi | Akut myeloid leukemi (AML) | Akut myelocytisk leukemi | Akut granulocytisk leukemi | Akut icke-lymfocytisk leukemiFörenta staterna
-
Institute of Hematology & Blood Diseases HospitalBejing Institute for Stem Cell and Regenerative Medicine; Institute for...RekryteringRefraktär leukemi | Återfallande leukemi | Akut myeloid leukemi, barndomKina
-
Betta Pharmaceuticals Co., Ltd.Har inte rekryterat ännuAkut Myeloid Leukemi LeukemiKina
-
Massachusetts General HospitalAvslutad
-
GlaxoSmithKlineAvslutadLeukemi, Myelocytisk, AkutFörenta staterna, Australien, Kanada
-
Hybrigenics CorporationOkändAkut myelogen leukemiFörenta staterna, Frankrike
-
Beijing Boren HospitalRekryteringAkut myeloid leukemi | Refraktär Akut Myeloid Leukemi | Återfall leukemiKina
-
M.D. Anderson Cancer CenterWake Forest UniversityAvslutadKronisk myelomonocytisk leukemi | Akut myelogen leukemiFörenta staterna
-
Sidney Kimmel Comprehensive Cancer Center at Johns...AvslutadAkut lymfoblastisk leukemi | Akut myelogen leukemi (AML) | Akut lymfatisk leukemi (ALL) | Akut promyelocytisk leukemi (APL)Förenta staterna
-
M.D. Anderson Cancer CenterRekryteringAkut myeloid leukemi | Terapi-relaterad akut myeloid leukemi | Akut bilineal leukemi | Akut bifenotypisk leukemi | T Akut lymfoblastisk leukemi | Blandad fenotyp Akut leukemiFörenta staterna